The addition of subcutaneous daratumumab to triplet therapy improved outcomes for certain patients with newly diagnosed multiple myeloma, study results showed.
The findings, published in Nature Medicine, support quadruplet therapy with subcutaneous daratumumab (Darzalex, Johnson & Johnson/Janssen), bortezomib (Velcade, Takeda), lenalidomide (Revlimid, Bristol Myers Squibb) and dexamethasone as a new standard of care for patients with transplant-ineligible or transplant-deferred multiple myeloma, researchers concluded.
“Daratumumab is the first monoclonal antibody that had shown